Department of Drug and Health Science, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
Curr Med Chem. 2022;29(24):4152-4169. doi: 10.2174/0929867329666220104111949.
This review describes the use of lipid-based nanocarriers (LNCs) for the parenteral delivery of pharmaceutical actives. Firstly, the two generations of LNCs, namely solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), are explained in terms of preparation, characterization and stability. Although the use of LNCs through parenteral administration has shown many benefits, their use is limited by opsonization, an immune process that causes their short half-life (3-5 min). Therefore, many strategies are discussed to realize "stealth" systems suitable for parenteral administration. The requirements and applications of parenteral lipid nanoparticles are reviewed for the delivery of natural compounds, synthetic drugs and genetic materials. Recently, the latter application has been of remarkable interest due to the numerous benefits of mRNA vaccines to fight the Covid-19 pandemic.
这篇综述描述了基于脂质的纳米载体（LNCs）在药物活性的 给药中的应用。首先，根据制备、表征和稳定性，解释了两代 LNCs，即固体脂质纳米粒（SLNs）和纳米结构脂质载体（NLCs）。尽管通过 给药使用 LNCs 已经显示出许多好处，但它们的使用受到调理作用的限制，这是一种导致其半衰期短（3-5 分钟）的免疫过程。因此，讨论了许多策略来实现适合 给药的“隐形”系统。综述了用于传递天然化合物、合成药物和遗传物质的 脂质纳米粒的要求和应用。最近，由于 mRNA 疫苗在抗击 COVID-19 大流行方面的诸多好处，后者的应用引起了人们的极大兴趣。
